These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
135 related items for PubMed ID: 15887718
1. Vogt-Koyanagi-Harada syndrome following injury-induced progressive vitiligo. Gupta V, Gupta A, Bambery P, Radotra BD, Pandav SS. Indian J Ophthalmol; 2001 Mar; 49(1):53-5. PubMed ID: 15887718 [Abstract] [Full Text] [Related]
7. [Vitiligo revealing Vogt -Koyanagi-Harada disease]. Amraoui ME, Zemmez Y, Bouhamidi A, Frikh R, Hjira N, Boui M. Pan Afr Med J; 2017 Mar; 27():220. PubMed ID: 28979622 [Abstract] [Full Text] [Related]
8. Vogt-Koyanagi-Harada disease and vitiligo: where does the illness begin? Prignano F, Betts CM, Lotti T. J Electron Microsc (Tokyo); 2008 Jan; 57(1):25-31. PubMed ID: 18174263 [Abstract] [Full Text] [Related]
9. Successful Treatment of Vitiligo Associated with Vogt-Koyanagi-Harada Disease. Bayer ML, Chiu YE. Pediatr Dermatol; 2017 Mar; 34(2):204-205. PubMed ID: 27981622 [Abstract] [Full Text] [Related]
12. Case Series: Gene Expression Analysis in Canine Vogt-Koyanagi-Harada/Uveodermatologic Syndrome and Vitiligo Reveals Conserved Immunopathogenesis Pathways Between Dog and Human Autoimmune Pigmentary Disorders. Egbeto IA, Garelli CJ, Piedra-Mora C, Wong NB, David CN, Robinson NA, Richmond JM. Front Immunol; 2020 Apr; 11():590558. PubMed ID: 33384688 [Abstract] [Full Text] [Related]
13. Vogt-Koyanagi-Harada syndrome associated with cutaneous malignant melanoma: an 11-year follow-up. Aisenbrey S, Lüke C, Ayertey HD, Grisanti S, Perniok A, Brunner R. Graefes Arch Clin Exp Ophthalmol; 2003 Dec; 241(12):996-9. PubMed ID: 14618342 [Abstract] [Full Text] [Related]
15. [Vogt-Koyanagi-Harada syndrome]. Serna-Ojeda JC, Pedroza-Seres M. Rev Fac Cien Med Univ Nac Cordoba; 2016 Sep; 73(2):132-3. PubMed ID: 27420148 [Abstract] [Full Text] [Related]
16. Humoral immune response directed against LEDGF in patients with VKH. Yamada K, Senju S, Shinohara T, Nakatsura T, Murata Y, Ishihara M, Nakamura S, Ohno S, Negi A, Nishimura Y. Immunol Lett; 2001 Oct 01; 78(3):161-8. PubMed ID: 11578690 [Abstract] [Full Text] [Related]
17. Vogt-Koyanagi-Harada syndrome: Perspectives for immunogenetics, multimodal imaging, and therapeutic options. Silpa-Archa S, Silpa-Archa N, Preble JM, Foster CS. Autoimmun Rev; 2016 Aug 01; 15(8):809-19. PubMed ID: 27060382 [Abstract] [Full Text] [Related]
18. Vogt-Koyanagi-Harada syndrome: Association with alopecia areata. Haque WM, Mir MR, Hsu S. Dermatol Online J; 2009 Dec 15; 15(12):10. PubMed ID: 20040260 [Abstract] [Full Text] [Related]
19. Bilateral Iris Depigmentation and Ocular Hypotony as End-Stage Manifestations of Untreated Vogt-Koyanagi-Harada Disease. Cuevas M, de-la-Torre A, Córdoba A. Ocul Immunol Inflamm; 2018 Dec 15; 26(7):1101-1106. PubMed ID: 28548582 [Abstract] [Full Text] [Related]
20. Vogt-Koyanagi-Harada syndrome. Greco A, Fusconi M, Gallo A, Turchetta R, Marinelli C, Macri GF, De Virgilio A, de Vincentiis M. Autoimmun Rev; 2013 Sep 15; 12(11):1033-8. PubMed ID: 23567866 [Abstract] [Full Text] [Related] Page: [Next] [New Search]